In chondrosarcomas (CSs), DAC treatment has been shown to hypomethylate Satellite 1 and L1 and overexpress genes like Sox-2 and midkine (MDK), leading to increased tumor invasiveness in some models while inhibiting growth in others [63,64]. This evidence concerns the gene MDK and chondrosarcoma.